Craig-Hallum Initiates Coverage On Lineage Cell Therapeutics with Buy Rating, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum has initiated coverage on Lineage Cell Therapeutics (AMEX:LCTX) with a Buy rating and set a price target of $4.
August 20, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Craig-Hallum has initiated coverage on Lineage Cell Therapeutics with a Buy rating and a price target of $4, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $4 by Craig-Hallum suggests a positive sentiment towards LCTX. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100